Chris is a Principal at Sanofi Ventures, joining in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting, where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors. In addition to his role as an observer on the Avilar board, Chris represents Sanofi on the boards of i2O Therapeutics and Minervax and is an observer for Matchpoint Therapeutics and Nextpoint Therapeutics. Chris also serves on the Board of Trustees at Roger Williams University. Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.
